Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats

Bone ◽  
2017 ◽  
Vol 97 ◽  
pp. 20-28 ◽  
Author(s):  
Yanfei L Ma ◽  
Matthew Hamang ◽  
Jonathan Lucchesi ◽  
Nicoletta Bivi ◽  
Qianqiang Zeng ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Mass ◽  
Bone Strength ◽  
Time Course ◽  
Ovariectomized Rats ◽  
Sclerostin Antibody

scholarly journals Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*

2009 ◽  
Vol 24 (4) ◽  
pp. 578-588 ◽  
Author(s):  
Xiaodong Li ◽  
Michael S Ominsky ◽  
Kelly S Warmington ◽  
Sean Morony ◽  
Jianhua Gong ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Mass ◽  
Postmenopausal Osteoporosis ◽  
Bone Strength ◽  
Rat Model ◽  
Antibody Treatment ◽  
Sclerostin Antibody

scholarly journals Increased Bone Formation and Bone Mass Induced by Sclerostin Antibody Is Not Affected by Pretreatment or Cotreatment with Alendronate in Osteopenic, Ovariectomized Rats

Endocrinology ◽  
2011 ◽  
Vol 152 (9) ◽  
pp. 3312-3322 ◽  
Author(s):  
Xiaodong Li ◽  
Michael S. Ominsky ◽  
Kelly S. Warmington ◽  
Qing-Tian Niu ◽  
Franklin J. Asuncion ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Mass ◽  
Ovariectomized Rats ◽  
Sclerostin Antibody

scholarly journals Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass and Bone Strength of Intact Bones in Adult Male Rats

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Pui Kit Suen ◽  
Tracy Y. Zhu ◽  
Dick Ho Kiu Chow ◽  
Le Huang ◽  
Li-Zhen Zheng ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Mass ◽  
Bone Strength ◽  
Adult Male ◽  
Male Rats ◽  
Antibody Treatment ◽  
Sclerostin Antibody

scholarly journals A New Synthetic Steroid, Osaterone Acetate (TZP-4238), Increases Cortical Bone Mass and Strength by Enhancing Bone Formation in Ovariectomized Rats

1997 ◽  
Vol 12 (4) ◽  
pp. 590-597 ◽  
Author(s):  
Hiroaki Fuse ◽  
Seiji Fukumoto ◽  
Hideyuki Sone ◽  
Yoshiko Miyata ◽  
Tomoyuki Saito ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Mass ◽  
Cortical Bone ◽  
Ovariectomized Rats ◽  
Cortical Bone Mass

Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice

Bone ◽  
2021 ◽  
pp. 116201
Author(s):  
Kelsey A. Carpenter ◽  
Reid Davison ◽  
Shruti Shakthivel ◽  
Kyle D. Anderson ◽  
Frank C. Ko ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Mass ◽  
Phosphate Metabolism ◽  
Sclerostin Antibody

scholarly journals Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice

2018 ◽  
Vol 238 (1) ◽  
pp. 13-23 ◽  
Author(s):  
Thomas Funck-Brentano ◽  
Karin H Nilsson ◽  
Robert Brommage ◽  
Petra Henning ◽  
Ulf H Lerner ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Loss ◽  
Bone Formation ◽  
Bone Mass ◽  
Trabecular Bone ◽  
Cortical Bone ◽  
Bone Strength ◽  
Bending Test ◽  
Bone Homeostasis ◽  
Mineral Density

WNT signaling is involved in the tumorigenesis of various cancers and regulates bone homeostasis. Palmitoleoylation of WNTs by Porcupine is required for WNT activity. Porcupine inhibitors are under development for cancer therapy. As the possible side effects of Porcupine inhibitors on bone health are unknown, we determined their effects on bone mass and strength. Twelve-week-old C57BL/6N female mice were treated by the Porcupine inhibitors LGK974 (low dose = 3 mg/kg/day; high dose = 6 mg/kg/day) or Wnt-C59 (10 mg/kg/day) or vehicle for 3 weeks. Bone parameters were assessed by serum biomarkers, dual-energy X-ray absorptiometry, µCT and histomorphometry. Bone strength was measured by the 3-point bending test. The Porcupine inhibitors were well tolerated demonstrated by normal body weight. Both doses of LGK974 and Wnt-C59 reduced total body bone mineral density compared with vehicle treatment (P < 0.001). Cortical thickness of the femur shaft (P < 0.001) and trabecular bone volume fraction in the vertebral body (P < 0.001) were reduced by treatment with LGK974 or Wnt-C59. Porcupine inhibition reduced bone strength in the tibia (P < 0.05). The cortical bone loss was the result of impaired periosteal bone formation and increased endocortical bone resorption and the trabecular bone loss was caused by reduced trabecular bone formation and increased bone resorption. Porcupine inhibitors exert deleterious effects on bone mass and strength caused by a combination of reduced bone formation and increased bone resorption. We suggest that cancer targeted therapies using Porcupine inhibitors may increase the risk of fractures.

Raloxifene preserves bone strength and bone mass in ovariectomized rats.

Endocrinology ◽  
1994 ◽  
Vol 135 (5) ◽  
pp. 2001-2005 ◽  
Author(s):  
C H Turner ◽  
M Sato ◽  
H U Bryant
Keyword(s):  
Bone Mass ◽  
Bone Strength ◽  
Ovariectomized Rats
Sign in / Sign up

Export Citation Format

Share Document